MEDIA

Grifols increases its revenues by 14.3% to EUR 2,423 million, driven by its strategic growth plan

July 16, 2019

Grifols presents additional encouraging Alzheimer’s trial results at AAIC

July 4, 2019

Grifols announces FDA approval of Xembify^®, 20% subcutaneous immunoglobulin for primary immunodeficiencies

Show more news

Media contacts

Journalist or media professional?

Our Media Relations team is available at:
(+34) 93 571 00 02
media@grifols.com.
Restricted to media inquiries only.

Not a journalist?

For general questions and requests, please contact corporatecomms@grifols.com.

Content: footer-organization-info

The information contained on the Grifols worldwide website is not applicable to all countries. For specific information on the products and services available in your country, please select your country from the list included in the corresponding section. The purpose of this website is to provide information about Grifols' products and services, and it is not intended for, nor may it be construed to, promoting any products in countries in which they are not approved.

MEDIA

Grifols increases its revenues by 14.3% to EUR 2,423 million, driven by its strategic growth plan

Grifols presents additional encouraging Alzheimer’s trial results at AAIC

Grifols announces FDA approval of Xembify®, 20% subcutaneous immunoglobulin for primary immunodeficiencies

Media contacts

Grifols announces FDA approval of Xembify^®, 20% subcutaneous immunoglobulin for primary immunodeficiencies